川宁生物
(301301)
| 流通市值：51.39亿 | | | 总市值：185.28亿 |
| 流通股本：6.19亿 | | | 总股本：22.32亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,097,724,481.88 | 1,094,498,381.4 | 4,616,269,644.24 | 3,435,984,280.4 |
| 营业收入 | 2,097,724,481.88 | 1,094,498,381.4 | 4,616,269,644.24 | 3,435,984,280.4 |
| 二、营业总成本 | 1,749,676,349.85 | 953,571,535.58 | 3,647,312,221.12 | 2,650,557,983.64 |
| 营业成本 | 1,545,897,128.68 | 836,666,749.51 | 3,265,956,722.8 | 2,308,976,930 |
| 税金及附加 | 35,770,499.69 | 17,149,406.82 | 67,207,801.83 | 55,640,708.47 |
| 销售费用 | 17,367,797.46 | 9,812,534.95 | 29,185,254.15 | 19,142,753 |
| 管理费用 | 85,422,292.64 | 54,360,747.13 | 152,018,398.84 | 157,758,113.09 |
| 研发费用 | 39,825,665.11 | 22,087,783.69 | 102,487,895.57 | 83,635,566.63 |
| 财务费用 | 25,392,966.27 | 13,494,313.48 | 30,456,147.93 | 25,403,912.45 |
| 其中:利息费用 | 18,322,662.45 | 8,929,055.47 | 33,819,574.98 | 30,820,819.32 |
| 其中:利息收入 | 1,530,796.02 | 674,202.68 | 4,657,248.26 | 3,904,504.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -217,381.95 | -901,170 | -1,483,217.89 | -226,400 |
| 加:投资收益 | -3,272,041.99 | -1,855,919.24 | -4,257,193.63 | -2,025,204.33 |
| 资产处置收益 | - | - | 345,957.83 | 352,143.38 |
| 资产减值损失(新) | -8,080,932.32 | - | -24,049,005.04 | -23,132,579.66 |
| 信用减值损失(新) | -1,707,307.23 | 309,759.01 | -3,688,329.89 | -8,114,710.29 |
| 其他收益 | 8,343,796.26 | 3,969,253.72 | 21,162,242.55 | 15,656,604.43 |
| 四、营业利润 | 343,114,264.8 | 142,448,769.31 | 956,987,877.05 | 767,936,150.29 |
| 加:营业外收入 | 1,049,385.38 | 177,947.83 | 1,412,570.67 | 179,734.41 |
| 减:营业外支出 | 6,860,741.05 | 3,921,555.39 | 19,714,639.98 | 16,341,088.27 |
| 五、利润总额 | 337,302,909.13 | 138,705,161.75 | 938,685,807.74 | 751,774,796.43 |
| 减:所得税费用 | 63,221,706.85 | 28,687,375.94 | 170,339,650.35 | 140,870,849.82 |
| 六、净利润 | 274,081,202.28 | 110,017,785.81 | 768,346,157.39 | 610,903,946.61 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 274,081,202.28 | 110,017,785.81 | 768,346,157.39 | 610,903,946.61 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 277,506,523.94 | 110,727,115.84 | 769,008,907.26 | 611,393,152.05 |
| 少数股东损益 | -3,425,321.66 | -709,330.03 | -662,749.87 | -489,205.44 |
| 扣除非经常损益后的净利润 | 271,809,082.26 | 109,477,326.95 | 758,207,774.98 | 607,985,214.8 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.05 | 0.34 | 0.27 |
| (二)稀释每股收益 | 0.12 | 0.05 | 0.34 | 0.27 |
| 八、其他综合收益 | - | - | 289,923.58 | - |
| 归属于母公司股东的其他综合收益 | - | - | 289,923.58 | - |
| 九、综合收益总额 | 274,081,202.28 | 110,017,785.81 | 768,636,080.97 | 610,903,946.61 |
| 归属于母公司股东的综合收益总额 | 277,506,523.94 | 110,727,115.84 | 769,298,830.84 | 611,393,152.05 |
| 归属于少数股东的综合收益总额 | -3,425,321.66 | -709,330.03 | -662,749.87 | -489,205.44 |
| 公告日期 | 2026-08-25 | 2026-04-23 | 2026-03-31 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |